edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Actinogen Medical
Edison Investment Research has terminated coverage on Actinogen Medical (ACW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Actinogen Medical — 1 video in collection
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11β-HSD1 inhibitor designed to prevent excess cortisol production in the brain and thereby reduce the progression of chronic neurodegenerative conditions such as Alzheimer’s disease (AD). Xanamem has also shown therapeutic activity in the treatment of major depressive disorder.
Listen on your preferred podcast player below:
About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.
Get access to the very latest content matched to your personal investment style.